ANGIOGENES PEPTID

European patent · EP2280988 · In force

Register entry

Publication number
EP2280988
Application number
EP09733863
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 23, 2009
Published
Feb 9, 2011
Granted
May 24, 2017
Protection ends at the latest
Apr 22, 2029
Next annual fee due
Apr 30, 2027
IPC classes
A61K 8/64 (2006.01)
A61Q 19/02 (2006.01)
A61Q 19/08 (2006.01)
A61K 38/00 (2006.01)
C07K 7/06 (2006.01)
Priority
US 47338 P 23.04.2008
PCT application
PCT/KR2009/002136 23.04.2009
PCT publication
WO2009/131395 29.10.2009
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 1, 2026

    Change

    Published in Swissreg on 01.05.2026

  2. May 1, 2025

    Change

    Published in Swissreg on 01.05.2025

  3. May 1, 2024

    Change

    Published in Swissreg on 01.05.2024

  4. Sep 4, 2023

    Address changed

    Representative
    BOHEST AG, Zweigniederlassung Ostschweiz, Postfach 147, 9471 Buchs → BOHEST AG, Zweigniederlassung Ostschweiz, Postfach, 9471 Buchs

    Published in Swissreg on 04.09.2023

  5. May 1, 2023

    Change

    Published in Swissreg on 01.05.2023

  6. Aug 3, 2017

    Agent entered

    Representative
    BOHEST AG, Zweigniederlassung Ostschweiz, Postfach 147, 9471 Buchs

    Published in Swissreg on 03.08.2017

  7. May 24, 2017

    Granted

    Published in Swissreg on 24.05.2017

Parties

Holder

Novacell Technology Inc.

Dept. Life Science 116, Pohang University of Science and Technology San 31, Hyoja-Dong, Nam-Gu, Pohang, Kyungbuk 790-784, KR

Agent

BOHEST AG

Zweigniederlassung Ostschweiz Postfach, 9471 Buchs

Inventor

LEE, Taehoon

Pohang Gyeongsangbuk-do 790-825, KR

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.